Viremia Copy-Years Predicts Mortality Among Treatment-Naive HIV-Infected Patients Initiating Antiretroviral Therapy by Mugavero, Michael J. et al.
M A J O R A R T I C L E H I V / A I D S
Viremia Copy-Years Predicts Mortality Among
Treatment-Naive HIV-Infected Patients
Initiating Antiretroviral Therapy
Michael J. Mugavero,1,a Sonia Napravnik,2,3,a Stephen R. Cole,3 Joseph J. Eron,2,3 Bryan Lau,4 Heidi M. Crane,5
Mari M. Kitahata,5 James H. Willig,1 Richard D. Moore,6 Steven G. Deeks,7 Michael S. Saag,1 and on behalf of the
Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort Study
1Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham; 2Department of Medicine, Division of Infectious
Diseases, and 3Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill; 4Department of Biostatistics, School
of Public Health, Johns Hopkins University, Baltimore, Maryland; 5Department of Medicine, Division of Infectious Diseases, University of Washington,
Seattle; 6Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland; and 7Department of Medicine,
Division of Infectious Diseases, University of California at San Francisco
Background. Cross-sectional plasma human immunodeficiency virus (HIV) viral load (VL) measures have
proven invaluable for clinical and research purposes. However, cross-sectional VL measures fail to capture
cumulative plasma HIV burden longitudinally. We evaluated the cumulative effect of exposure to HIV replication
on mortality following initiation of combination antiretroviral therapy (ART).
Methods. We included treatment-naive HIV-infected patients starting ART from 2000 to 2008 at 8 Center for
AIDS Research Network of Integrated Clinical Systems sites. Viremia copy-years, a time-varying measure of
cumulative plasma HIV exposure, were determined for each patient using the area under the VL curve. Multivariable
Cox models were used to evaluate the independent association of viremia copy-years for all-cause mortality.
Results. Among 2027 patients contributing 6579 person-years of follow-up, the median viremia copy-years was
5.3 log10 copy3 y/mL (interquartile range: 4.9–6.3 log10 copy3 y/mL), and 85 patients (4.2%) died. When evaluated
separately, viremia copy-years (hazard ratio [HR] 5 1.81 per log10 copy 3 y/mL; 95% confidence interval [CI],
1.51–2.18 per log10 copy 3 y/mL), 24-week VL (1.74 per log10 copies/mL; 95% CI, 1.48–2.04 per log10 copies/mL),
and most recent VL (HR 5 1.89 per log10 copies/mL; 95% CI: 1.63–2.20 per log10 copies/mL) were associated with
increased mortality. When simultaneously evaluating VL measures and controlling for other covariates, viremia copy-
years increased mortality risk (HR5 1.44 per log10 copy3 y/mL; 95% CI, 1.07–1.94 per log10 copy3 y/mL), whereas
no cross-sectional VL measure was independently associated with mortality.
Conclusions. Viremia copy-years predicted all-cause mortality independent of traditional, cross-sectional VL
measures and time-updated CD41 T-lymphocyte count in ART-treated patients, suggesting cumulative HIV
replication causes harm independent of its effect on the degree of immunodeficiency.
In the mid-1990s, plasma HIV RNA levels (or ‘‘viral
load’’ [VL]) emerged as an essential surrogate biomarker,
triggering a dynamic period of scientific discovery that
resulted in pivotal advances in our understanding of viral
pathogenesis and the natural history of HIV infection
[1–4]. Contemporaneous advances in combination an-
tiretroviral therapy (ART) allowed for landmark studies
demonstrating the prognostic value of plasma HIV VL
reduction on the occurrence of clinical disease pro-
gression following treatment initiation [5, 6]. Around the
same time, the significant role of plasma VL in relation to
HIV risk transmission was identified [7], providing the
foundation for a ‘‘test-and-treat’’ HIV prevention strat-
egy [8, 9]. Although plasma VL has been integral to HIV
clinical practice and research initiatives for more than
a decade, this biomarker has been used almost exclusively
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as a cross-sectional measure clinically and analytically, even
though it is routinely measured serially. Although single plasma
VL measures have demonstrated clear value in translational,
clinical, and prevention research, cross-sectional measures fail to
capture an individual’s cumulative exposure to viral replication
over time.
Historically, the pathogenesis of plasma HIV VL was largely
ascribed to the role of varying levels of viremia contributing to
differential rates of CD41 T lymphocyte decline [1, 2, 10, 11]. In
recent years, this paradigm has expanded with increased rec-
ognition of an independent association of viremia with mor-
bidity and mortality. These observations have largely been
ascribed to de novo viral replication as a driver of inflammatory
responses and immune system activation [12, 13]. Sustained
periods of HIV replication may cause irreversible damage to
the immune system, including lymphoid fibrosis, thymic de-
struction, exhaustion of hematopoietic stem cells, loss of gut
mucosal integrity, and end-organ disease [14–18]. The in-
flammatory process associated with viral replication may also
contribute to premature onset of atherosclerosis and other dis-
eases not traditionally associated with AIDS [12].
Cross-sectional VL measures fail to capture a patient’s lon-
gitudinal exposure to HIV replication. Measurement of cumu-
lative plasma VL burden is particularly relevant in the modern
treatment era, potentially serving as a proxy measure of cu-
mulative inflammation and immune system activation. More-
over, cumulative VL measures may also prove valuable in
modeling HIV transmission dynamics, particularly in the eval-
uation of test-and-treat prevention interventions and simulation
models [8, 9, 19].
We developed viremia copy-years as a measure of cumulative
HIV burden that estimates the area under a patient’s longitudinal
VL curve [20]. In this study, we evaluated the relationship between
viremia copy-years and mortality among patients who started
ART in a large, nationally distributed cohort receiving HIV care in
the United States. We hypothesized a strong, positive relationship
would be observed between viremia copy-years and the risk of
all-cause mortality, independent of patient socio-demographic
and clinical prognostic factors, including clinically relevant cross-
sectional VL measures (baseline, 24-week, and most-recent VL
measures) and time-updated CD41 T-lymphocyte count.
METHODS
Sample and Procedures
The Centers for AIDS Research (CFAR) Network of Integrated
Clinical Systems (CNICS) is a nationally distributed HIV clinical
cohort that has been described in detail previously [21]. The
CNICS cohort includes .21000 HIV-infected adults (contribut-
ing.60000 person-years follow-up) who have received HIV care
at 1 of 8 CFAR sites, dating back to 1995. Every 2 months, sites
transmit comprehensive and well-defined data elements captured
from point-of-care electronic health-record systems using stan-
dardized terminology and format. The participating cohorts and
this study were approved by local institutional review boards.
For this study, we included all antiretroviral-naive CNICS
patients who started ART with at least 3 antiretroviral agents
including either a ritonavir-boosted protease inhibitor (PI/r)
or a nonnucleoside reverse transcriptase inhibitor (NNRTI)
between 1 January 2000 and 31 December 2008 (n5 3075). We
excluded patients with ,24 weeks of follow-up (n 5 313),
without available pre-ARTVL or CD4 cell count values (n5 355),
or without at least 2 VL measures following ART initiation
(n5 380). Patients were followed until the first of death from any
cause; administrative censoring (July 31, 2009); or loss to follow-
up defined as not having a VL measured in .12 months (with
censoring at last available VL 1 365 days).
Plasma Viral Load Measures
VL values obtained during routine clinical care were used for all
analyses. The most commonly used VL assays were the Amplicor
HIV-1 Ultrasensitive Monitor test (Roche Molecular Systems,
40%), Amplicor HIV-1 Monitor test (Roche Molecular Systems,
13%), other reverse-transcription polymerase chain reaction–
based tests (21%), and quantitative branched DNA tests (25%).
Values below a limit of assay detection were set to one-half the
limit of detection for that assay. Cross-sectional VL measures
used for analyses were selected based on clinical relevance and
long-standing use in the published literature and included:
baseline VL (most proximal within 6 months prior to ART
initiation), 24-week VL following ART initiation, and most re-
cent VL (observed.24 weeks post–ART initiation) [10, 22–24].
Viremia copy-years, the principal exposure of interest, is
a time-varying measure of cumulative plasma HIV burden, akin
to pack-years of cigarette smoking, which is calculated using
methods described previously [20]. The trapezoidal rule is used
to approximate the integral representing the area under each
patient’s longitudinal VL curve. VL burden for each segment
(time interval between 2 consecutive VL values) is calculated by
multiplying the mean of the 2 VL values by the time interval. The
copy 3 y/mL for each segment of a patient’s VL curve are then
summed to calculate viremia copy-years. Formally, viremia copy-
years is the number of copies of HIV RNA per mL of plasma over
time. For example, 10 000 copy-years of viremia is equal to having
a VL of 10000 copies/mL for 1 year or a VL of 1000 copies/mL
for 10 years. VL values prior to 24 weeks of ART initiation were
excluded from calculating viremia copy-years to best capture the
effect of cumulative VL exposure on mortality after allowing
patients a reasonable window to respond to therapy.
Mortality Ascertainment
Mortality data were obtained from clinic sources and confirmed
by the National Death Index, Social Security Death Index, or
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state death certificate data. These databases were searched at least
annually for all CNICS participants who were not known to be
alive. Because cause of death is subject to misclassification and
often unknown, we did not evaluate cause-specific mortality.
Additional Covariates
Additional measures selected a priori included age, sex, race/
ethnicity, men who have sex with men (MSM), and injection-
drug use (IDU) as HIV risk transmission groups, year of ART
initiation, PI/r- vs NNRTI-based initial ART regimen, baseline
and time-updated CD41 T-lymphocyte counts, and CNICS
site. We used an intention-to-continue initial ART regimen
approach and therefore did not account for changes or dis-
continuation of ART regimens [25].
Statistical Analyses
Spearman rank correlation coefficient was used to assess cor-
relation between VL measures. Mortality rates were expressed as
deaths per 100 person-years with 95% confidence intervals based
on an exact Poisson distribution. Cox proportional hazards
regression models were used to estimate the relationship be-
tween viremia copy-years and all-cause mortality, with time at
risk accrued from 24 weeks post–ART initiation. Multivariable
models were adjusted for covariates outlined above. Because
viremia copy-years is affected by prior viremia copy-years and
CD41 T-lymphocyte counts, which themselves are affected by
prior viremia copy-years, we used inverse probability–weighted
marginal structural models [25, 26]. We estimated the inverse
probability weights by fitting linear regressionmodels to estimate
each patient’s density of viremia copy-years. This is an extension
of the previously outlined [26] standard marginal structural
model with a binary treatment variable to that of a continuous
variable. These models included the baseline and time-varying
factors listed previously, where time-varying covariates were
lagged by 1 visit to ensure proper temporal ordering.
We also adjusted for selection bias by estimating inverse
probability of censoring weights and for differential attendance
at clinic visits by estimating inverse probability of visit atten-
dance weights [27]. These weights were conditional on mea-
sured baseline and time-varying covariates. Weights based on a
density (eg, viremia copy-years) and probabilities (eg, censoring
and visit attendance) were stabilized, the latter to improve effi-
ciency. The mean of the estimated stabilized inverse probability
weights was 1.00 (standard deviation, 0.24; minimum/maximum,
0.27/1.63). We fit a pooled logistic regression model weighted by
the product of these weights to approximate a weighted Cox
proportional hazards model [28]. The reference hazard was
modeled using cubic splines and robust 95% confidence intervals
were used. Departures from linearity were assessed by catego-
rizing continuous measures. The proportional hazards assump-
tion was explored graphically and assessed by inclusion of
a product term with time. We plotted survival curves stratified by
levels of time-updated viremia copy-years adjusted by inverse
probability unstabilized weights, which were a product of viremia
copy-years density weight, censoring weight, and visit-attendance
weight, as described above [29].
Additional models included cross-sectional VL measures,
which were evaluated individually and collectively in separate
models. Analogous steps to those for viremia copy-years were
followed to estimate inverse probability weights for most-recent
VL used in analyses where this was the main exposure of interest.
Because baseline and 24-week VLs are time-fixed, we did not
construct inverse probability weights for these VL measures when
they were the main exposure of interest; however, censoring and
visit attendance weights were constructed as above. Sensitivity
analyses were conducted assigning undetectable VL measures
a value of zero, varying the start time of viremia copy-years cal-
culation (from ART start, 48 weeks and 2-year post–ART-start),
censoring patients at ART discontinuation (gaps in ART.30 days
and .90 days), and excluding VL values proximal to death
(within 30 and 90 days), all of which yielded estimates for viremia
copy-years and mortality that were highly consistent with primary
analyses (data not shown). All statistical analyses were performed
using SAS version 9.2 (SAS Institute).
RESULTS
Among 2027 patients, the median age at ART initiation was
39 years (interquartile range [IQR]. 33–45 y), 81% were
male, 52% were Caucasian/white, 36% were African American/
black, and 54% were MSM (Table 1). The median baseline
CD41 T-lymphocyte count and VL were 222 cells/mm3
(IQR, 97–325 cells/mm3) and 4.8 log10 copies/mL (IQR, 4.2–5.3
log10 copies/mL), respectively. Of all patients, 30% started ART
with a PI/r-based regimen. The median year of ART initiation
was 2003 (IQR, 2002–2005). Patients were followed for a me-
dian of 2.7 years (IQR: 1.6–4.6) and contributed a total of
6579 person-years follow-up; 15% of patients (n 5 296) had
.12 months between VL measures during follow-up and were
considered lost to follow-up.
Patients contributed a median of 8 VL measures (IQR, 4–15),
for a total of 21665 VL measures. Most patients were virologi-
cally suppressed 24 weeks following ART initiation (n 5 1635,
81%). During follow-up, most VL measures were below the
limit of assay detection (n 5 17 764, 82%). Over time, the
median viremia copy-years was 5.3 log10 copy 3 years/mL
(IQR, 4.9–6.3). Viremia copy-years was poorly correlated with
baseline VL and somewhat correlated with 24-week and most-
recent VLs (Table 2).
In all, 4% of patients died (n5 85), for an overall mortality
rate of 1.3 deaths per 100 person-years (95% confidence
interval [CI], 1.0–1.6 deaths). The median time until death
was 2.0 years (IQR, 1.4–2.9 years). The unadjusted mortality
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hazard ratio (HR) for log10 viremia copy 3 years was
1.81 (95% CI: 1.51–2.18), indicating that for each log10 increase
in viremia copy-years the hazard of death increased nearly 2-
fold (Table 3). The increasing risk of death with greater viremia
copy-years was confirmed after categorizing viremia copy-years
and comparing the groups with 5–7 log10 viremia copy3 y/mL
(HR 5 1.38; 95% CI, 0.61–3.13) and .7 log10 viremia copy 3
y/mL (HR5 5.54; 95% CI, 3.46–8.84) to patients with,5 log10
viremia copy y/mL (Figure 1). The effect of viremia copy-years
on mortality did not vary appreciably across time.
In unadjusted and unweighted analyses, cross-sectional VL
measures following ART initiation, but not baseline VL, were
predictive of mortality; 24-week log10 VL (HR 5 1.74; 95%
CI: 1.48, 2.04) and most recent log10 VL (HR 5 1.89; 1.63,2.20,
Table 1. Characteristics of 2027 Treatment-Naive HIV-Infected Patients at Initiation of Combination Antiretroviral Therapy and Over the
Course of 6579 Person-Years Follow-up, CFAR Network of Integrated Clinical Systems (CNICS), 2000–2008a
Characteristic Baseline Follow-up
Participants/observations 2027 patients 21 665 VL measures
Age, years 39 (33–45) 42 (35–48)
Sex
Male 1646 (81%) 17 117 (79%)
Female 381 (19%) 4548 (21%)
Race/ethnicity
Caucasian/white 1045 (52%) 10 580 (49%)
African American/black 731 (36%) 8482 (39%)
Other 251 (12%) 2603 (12%)
Men who have sex with men 1085 (54%) 11 157 (52%)
Intravenous drug use 303 (15%) 3355 (15%)
ART initiation year
2000–02 466 (23%) 7673 (35%)
2003–05 765 (38%) 9453 (44%)
2006–08 796 (39%) 4539 (21%)
Initial ART regimen
NNRTI-based 1414 (70%) 15 150 (70%)
PI/r-based 613 (30%) 6515 (30%)
Baseline CD4 cell count, cells/mm3 222 (97–325) 197 (74–310)
Most recent CD4 cell count, cells/mm3 N/A 363 (208–541)
Baseline VL, log10 copies/mL 4.8 (4.2–5.3) 4.9 (4.2–5.4)
24-week VL ,2.6, log10 copies/mL 1635 (81%) 17 091 (79%)
Most recent VL, log10 copies/mL N/A ,2.6 (,2.6–,2.6)
Viremia copy-years, log10 copy 3 y/mL N/A 5.3 (4.9–6.3)
Follow-up, years 2.7 (1.6–4.6) N/A
VL measures contributed N/A 8 (4–15)
Abbreviations: ART, combination antiretroviral therapy; HIV, human immunodeficiency virus; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PI/r, ritonavir-boosted protease inhibitor; VL, plasma HIV viral load.
a Data are presented as N (%) or median (interquartile range) unless otherwise specified.
Table 2. Spearman Rank Correlation Matrix for Measures of Plasma HIV Viral Load Among 2027 Treatment-Naive HIV-Infected Patients
Initiating Combination Antiretroviral Therapy, CFAR Network of Integrated Clinical Systems (CNICS), 2000–2008
Viremia copy-years Baseline VL 24-week VL Most recent VL
Viremia copy-years, copy 3 y/mL 1
Baseline VL, copies/mL 0.10 1
24-week VL, copies/mL 0.45 0.08 1
Most recent VL, copies/mL 0.50 0.02 0.40 1
Abbreviations: HIV, human immunodeficiency virus; VL, plasma HIV viral load.
For repeat measures (viremia copy-years and most recent VL) the most recent value was used.
All P values for correlations are ,.01 except for baseline VL and most recent VL (P 5 .624).
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Table 3). In a combined VL model that included baseline,
24-week, andmost recent VL, the effect of viremia copy-years was
only slightly attenuated (HR5 1.62; 95% CI: 1.25, 2.11, Table 3).
In adjusted and weighted analyses, viremia copy-years was
independently associated with mortality (HR 5 1.65; 95% CI:
1.32, 2.06, Table 4). Results for each cross-sectional VL measure
individually were consistent with unadjusted and unweighted
results, albeit with attenuation of effect sizes (Table 4). In ad-
justed and weighted analyses that included demographic and
clinical covariates as well as baseline, 24-week, and most-recent
VL, the effect of viremia copy-years decreased slightly (HR5 1.44;
95% CI, 1.07–1.94); however, the cross-sectional VL measures
were no longer associated with mortality (Table 4). In addition
to viremia copy-years, lower most recent CD41 T-lymphocyte
count (0.72 per 100 cells/mm3; 95% CI, .61–.86) and older age
(HR 5 1.51 per 10 y; 95% CI, 1.18–1.94) were associated with
increased mortality risk.
DISCUSSION
Viremia copy-years, a measure of cumulative plasma HIV RNA
exposure and de novo viral replication, demonstrated a strong
association with all-cause mortality in a large sample of HIV-
infected patients who started ART.When controlling for clinically
meaningful, cross-sectional and time-updated VL measures and
time-updated CD41 T-lymphocyte count, as well as other co-
variates, an independent 44% increase in mortality risk
was observed per 1 unit increase in log10 copy 3 year/mL of
cumulative VL burden. We suggest viremia copy-years play an
important and complementary role to cross-sectional VL meas-
ures and transform the role of VL in future translational, clinical,
and prevention research initiatives, as well as clinical care.
Cross-sectional VL measures obtained at various single time
points in HIV-infected patient’s trajectory have provided im-
portant prognostic value in the eras preceding and following the
introduction of modern ART [1, 2, 5, 6, 11, 22–24]. Baseline VL
demonstrated clear prognostic value for disease progression
prior to the combination ART era [1, 2]. However, in the
modern treatment era, baseline VL is poorly predictive of clin-
ical events following ART start, whereas single, cross-sectional
VL measures on treatment (eg, 6-month) have proven valuable
in predicting AIDS and non-AIDS clinical events, including
mortality [22–24]. As expected, in the current study, cross-sec-
tional measures of 24-week and most-recent VLs were predictive
for all-cause mortality when evaluated individually. However,
these findings were substantially attenuated when controlling for
viremia copy-years in adjusted models.
In addition to viremia copy-years, a 51% increased mortality
risk for each additional 10 years of age at ART start, and a 28%
reduction in risk per additional 100 cells/mm3 in time-updated
CD41 T-lymphocyte count, was observed. The association of
viremia copy-years with mortality when controlling for most re-
cent CD41 T-lymphocyte count is particularly noteworthy. These
findings substantiate growing recognition that HIV replication
may cause or accelerate disease independent of its effect on pe-
ripheral CD41 T-cell depletion. In this regard, the relationship
between plasma HIV VL and markers of inflammation or im-
mune system activation have gained considerable attention, par-
ticularly in relation to the occurrence of non–AIDS-related clinical
events [12, 13].
In primary study analyses of the Strategic Management of
Antiretroviral Therapy (SMART) trial, the proportion of follow-
up time with detectable plasma viremia, all-cause mortality and
other clinical events were significantly higher among the drug
Table 3. All-Cause Mortality Following Initiation of Combination Antiretroviral Therapy Among 2027 Treatment-Naive HIV-Infected
Patients According to Viremia Copy-Years and Other Viral Load Measures, CFAR Network of Integrated Clinical Systems, 2000–2008
Hazard ratio 95% confidence limits P value
Separate VL models, unadjusted and unweighted:a
Viremia copy-years, log10 copy 3 y/mL 1.81 1.51, 2.18 ,.001
Baseline VL, log10 copies/mL 1.26 0.96, 1.64 .09
24-week VL, log10 copies/mL 1.74 1.48, 2.04 ,.001
Most recent VL, log10 copies/mL 1.89 1.63, 2.20 ,.001
Combined VL model, unadjusted and unweighted:b
Viremia copy-years, log10 copy 3 y/mL 1.62 1.25, 2.11 ,.001
Baseline VL, log10 copies/mL 1.08 0.85, 1.37 .54
24-week VL, log10 copies/mL 1.11 0.91, 1.34 .31
Most recent VL, log10 copies/mL 1.23 1.01, 1.49 .04
Abbreviations: HIV, human immunodeficiency virus; VL, plasma HIV viral load.
Models do not control for covariates, are not inverse probability weighted, and were fit via Cox proportional hazards regression.
a Separate Cox models were fit for each VL measure listed.
b One combined Cox model includes all VL measures listed.
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conservation arm, which received intermittent ART, relative to
the viral suppression group [30]. Notably, an increased, albeit
attenuated, risk of opportunistic diseases or death was observed
in the drug conservation arm of the SMART study even after
reinitiating continuous ART [31]. Among patients in the drug
conservation arm of the study, a strong, positive relationship
was observed between change in plasma HIV VL and change in
inflammatory biomarkers interleukin-6 and D-dimer, both of
which were associated with all-cause mortality [12]. SMART
study authors postulated long-term effects of elevated in-
flammatory biomarkers contributed to the excess residual risk of
clinical events in the drug conservation group even after re-
suming continuous ART. We speculate the number of viremia
copy-years, as a measure of cumulative plasma HIV burden,
serves as a surrogate for and perhaps is the underlying driver of
cumulative inflammation and immune system activation that
approximates such long-term inflammatory biomarker effects.
As patients with HIV infection in developed countries are living
longer and increasingly experiencing morbidity and mortality
from non-AIDS events [24, 32–35], many of which are associ-
ated with inflammation and immune system activation [12, 13],
cumulative measures of HIV burden may take on increased
importance in the coming years.
In recent years, others have begun to evaluate longitudinal
plasma HIV VL measures. Short-term area under the curve VL
measures (48–56 weeks post–ART initiation) relative to baseline
VL values have been evaluated in clinical trials as a predictor of
clinical events and used as an outcome measure [36, 37]. Ad-
ditionally, a recent study identified a strong association between
longer-term cumulative viremia and AIDS-related lymphoma
among patients receiving combination ART [38].
Our study has limitations. As with all observational studies,
we can identify associations but not ascribe causality because our
findings are subject to possible uncontrolled confounding.
Plasma VL measures were assessed relatively infrequently, with
variable numbers and timing of measures observed for patients,
reflecting the realities of HIV clinical care. We used inverse
probability weighting to account for between-patient heteroge-
neity in number and timing of VL measures in an effort to
address this limitation. We evaluated the effect of viremia copy-
years on mortality over a relatively short follow-up period; fu-
ture studies are needed to validate the prognostic value of this
Figure 1. Adjusted survival curve for time-varying viremia copy-years among 2027 treatment-naive HIV-infected patients, CFAR Network of Integrated
Clinical Systems (CNICS), 2000–2008. Adjusted survival curves modeling all-cause mortality among 2027 treatment-naive HIV-infected patients following
antiretroviral therapy (ART) initiation stratified by levels of time-updated viremia copy-years. Viremia copy-years, the principal exposure of interest, is
a time-varying measure of cumulative plasma HIV burden calculated as described in the methods section. Viral load values prior to 24 weeks of ART
initiation were excluded from calculating viremia copy-years to best capture the effect of cumulative viral load exposure on mortality after allowing
patients a reasonable window to respond to therapy. The survival curves were adjusted for confounding and selection bias due to age, sex, race/ethnicity,
HIV transmission risk group, initial ART, year of ART initiation, CNICS site, most recent CD4 count, and visit frequency using inverse probability
unstabilized weights, which were a product of viremia copy-years density weight, censoring weight, and visit attendance weight.
932 d CID 2011:53 (1 November) d HIV/AIDS
measure over longer follow-up. Specifically, studies are indicated
to further elucidate the predictive value of viremia copy-years
among patients who achieve and maintain virologic suppression
over longer follow-up, who experience brief periods of detect-
able viremia and those who experience periods of detectable
low-level viral replication. We had insufficient information on
cause-specific mortality to evaluate the relationship between
viremia copy-years with AIDS and non-AIDS deaths.
In conclusion, viremia copy-years, a novel measure of cu-
mulative plasma HIV burden, demonstrated prognostic value
for all-cause mortality independent of traditional, clinically
relevant cross-sectional VL measures and time-updated CD41
T-lymphocyte count in patients who started modern ART. Fu-
ture research should evaluate the relationship between viremia
copy-years and biomarkers of inflammation and immune sys-
tem activation longitudinally, as well as the value of this measure
in predicting AIDS and non-AIDS clinical events, and in mod-
eling HIV risk transmission over time.
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Most recent VL, log10 copies/mL 1.50 1.24, 1.81 ,.001
Combined VL model, adjusted and weighted:b
Viremia copy-years, log10 copy 3 y/mL 1.44 1.07, 1.94 .02
Baseline VL, log10 copies/mL 0.99 0.77, 1.27 .93
24-week VL, log10 copies/mL 1.07 0.87, 1.32 .51
Most recent VL, log10 copies/mL 1.15 0.94, 1.41 .18
Most recent CD4 cell count (per 100 cells/mm3) 0.72 0.61, 0.86 ,.001
Age (per 10 years) 1.51 1.18, 1.94 .001
Female 1.26 0.69, 2.29 .45
Caucasian/white race/ethnicity 1.78 1.13, 2.81 .01
Men who have sex with men 0.88 0.52, 1.47 .62
Intravenous drug use 0.86 0.47, 1.54 .60
PI/r-based initial ART regimen 1.50 0.94, 2.40 .09
Year of ART initiation (per 1 year increase) 1.02 0.91, 1.14 .75
All estimates are adjusted for baseline covariates including age, sex, race/ethnicity, HIV transmission risk group, initial ART, year of ART initiation, and CNICS site.
Additionally, time-varying covariates including most recent CD41 T-lymphocyte count were controlled through the inverse probability weights for time-varying VL
measures. Inverse probability weights were used in all models to control for selection bias and visit frequency.
Abbreviations: ART, combination antiretroviral therapy; HIV, human immunodeficiency virus; PI/r, ritonavir-boosted protease inhibitor; VL , plasma HIV viral load.
a Separate Cox models were fit for each VL measure listed.
b One combined Cox model includes all VL measures listed.
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